VGXI Begins Expansion at Woodlands, Texas, Production Center
02/23/2018
According to company officials, once completed the project will increase the company’s footprint by 17% and its cGMP manufacturing space by over 70%.
The upcoming development will add two new flexible-use GMP production areas to serve clients with both large and small scale needs, and a range of products from DNA vaccines to plasmid raw material for GMP viral vector production.
“With three key approvals in 2017 for CAR-T and AAV therapies, the gene therapy industry is rapidly maturing,” said VGXI’s President & CEO, Young Park. “We are excited to support the needs of our growing client base with increased flexibility and capacity across all service levels from Pre-Clinical to Highly Documented (HD) and cGMP grade plasmid production.”
VGXI, a wholly-owned subsidiary CMO of South Korea-based GeneOne Life Science, Inc., was founded in 1997 and has been operating as a GMP plasmid contract manufacturing organization since 2004. Over the 15 year period, the company said it has continued to grow in response to an increasing demand for high quality DNA, with its most recent expansion completed in 2016.
Most Read
-
-
On the Hunt for a Productive New Biomanufacturing Site?
Q4 2021
-
Changes in the Incentives Landscape
Q3 2021
-
Solutions for Decisively Navigating the Location Decision
Q4 2021
-
The Challenges of Renovating an Existing Facility Into a Food Plant
Q4 2021
-
First Person: Creating a Work Environment For Employee Growth and Development
Q4 2021
-
The “Great Resignation” Is Impacting Corporate Relocations
Workforce Q4 2021